BioAtla enters underwriting agreement to sell 9.745M shares at $6.67/share for $65M gross proceeds

BioAtla, Inc.

Offering of 9,745,128 common shares at $6.67 each; gross proceeds $65M before discounts and expenses.
Underwriter J.P. Morgan Securities LLC; closing expected Nov 8, 2022 subject to customary conditions.
Offering made under Form S-3 shelf registration (File 333-262528) declared effective May 18, 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioAtla, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC valued at $65,000,004.00 (effective 2022-11-04).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC
Value: $65,000,004.00
Effective: 2022-11-04

Exact text from the filing

On November 4, 2022, BioAtla, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as underwriter (the “Underwriter”), pursuant to which, the Company agreed to issue and sell to the Underwriter, and the Underwriter has agreed to purchase from the Company, an aggregate of 9,745,128 shares (the “Shares”) of its common stock, par value $0.0001 per share.

View on SEC.gov

Browse all material agreements →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-279214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.